JNNP: Plasma Aβ as a biomarker for predicting Aβ-PET findings in Alzheimer's disease patients

Alzheimer's disease (AD) is a neurodegenerative disease characterized by abnormal accumulation of amyloid beta (aβ) and hyperphosphorylation of tau protein

Fortunately, long-term presymptomatic stages of AD make it possible to intervene early with disease-modifying therapies

Currently, Aβ pathology can be identified by biomarker levels of amyloid-β positron emission tomography (Aβ-PET)

Patients assessed using Aβ-PET scans and plasma Aβ were included in this meta-analysis by searching online databases, including Embase, PubMed, and the Cochrane library

Patients assessed using Aβ-PET scans and plasma Aβ were included in this meta-analysis by searching online databases, including Embase, PubMed, and the Cochrane library

The meta-analysis included 16 studies with a total of 3047 participants

The meta-analysis included 16 studies with a total of 3047 participants

Meta-analysis results of Aβ40 group

Meta-analysis results of Aβ40 group

In this meta-analysis, it was found that plasma Aβ40 values ​​may not differ between PET (+) and PET (−)

In this meta-analysis, it was found that plasma Aβ40 values ​​may not differ between PET (+) and PET (−)

Egger'stest results in Aβ40 group

Egger's 

This meta-analysis provides evidence that plasma Aβ40 values ​​may not discriminate between PET(+) and PET(−) people.

ChengL ,LiW ,ChenY Cheng  LCheng Li  WLi Chen  YChen, et alPlasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease: a systematic review with meta-analysisJournal of Neurology, Neurosurgery & Psychiatry  Published Online First:  03 March 2022.
 Published Online First: doi:  10.
1136/jnnp-2021-327864doi:

leave a message here